4'-thio-arabinofuranosylcytosine

structure in first source

Also Known As:

4'-thio-beta-D-arabinofuranosylcytosine; 4-Amino-1-(4-thio-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone; OSI-7836; thiarabine; 2(1H)-Pyrimidinone, 4-amino-1-(4-thio-beta-D-arabinofuranosyl)-

Networked: 15 relevant articles (3 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Arabinonucleosides: 1
    - 4'-thio-arabinofuranosylcytosine: 15

Experts

1.	Parker, William B: 5 articles (01/2012 - 03/2003)
2.	Secrist, John A: 5 articles (01/2012 - 03/2003)
3.	Waud, William R: 4 articles (01/2012 - 06/2006)
4.	Gilbert, Karen S: 3 articles (01/2012 - 01/2012)
5.	Someya, Hitoshi: 3 articles (06/2006 - 03/2003)
6.	Parker, W B: 2 articles (01/2015 - 12/2000)
7.	Secrist, J A: 2 articles (01/2015 - 12/2000)
8.	Waud, W R: 2 articles (01/2015 - 12/2000)
9.	Tiwari, Kamal N: 2 articles (09/2006 - 03/2003)
10.	Drolet, Daniel W: 2 articles (05/2006 - 03/2006)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2015 - "Because of its impressive activity against numerous human tumor xenografts in mice, its unique biochemical activity, and encouraging clinical results in phase I clinical trials, we believe thiarabine should continue to be evaluated in the clinic for treatment of hematologic and/or solid tumors. " 11/01/2006 - "To determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety, tolerability, toxicity profile, dose-limiting toxicities (DLTs), anti-tumor activity and pharmacokinetics of OSI-7836 given IV on day 1 and day 8 every 3 weeks in patients with advanced incurable cancer. " 06/01/2006 - "Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine." 01/01/2015 - "Thiarabine has been evaluated in three phase I clinical trials, where it has demonstrated some activity in heavily pretreated patients with hematologic malignancies and solid tumors. " 12/15/2004 - "OSI-7836 (4'-thio-araC, T-araC) is a nucleoside analogue that shows efficacy against solid tumor xenograft models. "
2.	Fatigue 05/01/2006 - "OSI-7836 was associated with excessive fatigue, and despite changes in its schedule and duration of administration, we did not observe an improvement in its tolerability. " 03/01/2006 - "These findings show a toxicological profile with OSI-7836 similar to other nucleoside analogues and suggest that the beagle is a model for studying one possible cause of OSI-7836-related fatigue, impaired function of the hypothalamic-pituitary-adrenal axis." 03/01/2006 - "Fatigue is also associated with the use of gemcitabine and OSI-7836 in humans. "
3.	Leukemia 01/01/2012 - "Thiarabine warrants future clinical trials with leukemias/lymphomas." 01/01/2012 - "Preclinical antitumor activity of thiarabine in human leukemia and lymphoma xenograft models." 01/01/2012 - "Thiarabine was active against all of the human leukemia and lymphoma lines tested, being curative against HL-60 leukemia and AS283 lymphoma and effecting tumor regressions in CCRF-CEM, MOLT-4, and K-562 leukemia and RL lymphoma models, but did not exhibit any appreciable activity against RPMI-8226 myeloma. " 01/01/2012 - "Thiarabine was evaluated for antitumor activity in seven human leukemia, lymphoma, and myeloma xenograft models to explore the activity in hematological malignancies. " 01/01/2012 - "There appeared to be little, if any, difference in the metabolism of deoxycytidine, cytidine, or thiarabine in the two leukemias."
4.	Lymphoma (Lymphomas) 01/01/2012 - "Thiarabine warrants future clinical trials with leukemias/lymphomas." 01/01/2012 - "Preclinical antitumor activity of thiarabine in human leukemia and lymphoma xenograft models." 01/01/2012 - "Thiarabine was active against all of the human leukemia and lymphoma lines tested, being curative against HL-60 leukemia and AS283 lymphoma and effecting tumor regressions in CCRF-CEM, MOLT-4, and K-562 leukemia and RL lymphoma models, but did not exhibit any appreciable activity against RPMI-8226 myeloma. " 01/01/2012 - "Thiarabine was evaluated for antitumor activity in seven human leukemia, lymphoma, and myeloma xenograft models to explore the activity in hematological malignancies. " 01/01/2012 - "The antitumor activity of thiarabine in combination appeared to be greater than additive with irinotecan (DLD-1 colon), paclitaxel (PC-3 prostate), cisplatin (PC-3 prostate), or cyclophosphamide (RL lymphoma), additive with irinotecan (NCI-H460 NSCLC), cisplatin (NCI-H460 NSCLC) or methotrexate (CCRF-CEM leukemia), and less than additive with irinotecan (HT29 colon), paclitaxel (NCI-H460 NSCLC) or cisplatin (NCI-H23 NSCLC). "
5.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2015 - "Thiarabine has been evaluated in three phase I clinical trials, where it has demonstrated some activity in heavily pretreated patients with hematologic malignancies and solid tumors. " 01/01/2012 - "Thiarabine was evaluated for antitumor activity in seven human leukemia, lymphoma, and myeloma xenograft models to explore the activity in hematological malignancies. " 03/01/2011 - "The search terms used were clofarabine, nelarabine, forodesine, 8-chloroadenosine, LMP-420, azacitidine, decitabine, sapacitabine, troxacitabine, thiarabine and zebularine in conjunction with hematologic malignancies, leukemia and lymphoma. "

Related Drugs and Biologics

1.	Nucleosides
2.	Deoxycytidine
3.	DNA (Deoxyribonucleic Acid)
4.	Investigational Drugs
5.	Cytarabine (Cytosar-U)
6.	Gemcitabine
7.	Clofarabine (Clolar)
8.	Cladribine
9.	Paclitaxel (Taxol)
10.	Nucleotides

Related Therapies and Procedures

1.	Therapeutics
2.	TP protocol